Cutaquig Market Report 2026

Cutaquig Market Overview

• The Cutaquig market growth in the historic period has been driven by clinical success of immunoglobulin therapy, increased awareness of primary immunodeficiency • Market expansion is supported by growth of home infusion models, rising immune disorder prevalence • Growth Driver: Rising Prevalence Of Immunodeficiency Diseases Driving Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cutaquig Market?

Cutaquig is a subcutaneous immunoglobulin (SCIG) therapy used to treat primary immunodeficiency (PI), a group of disorders that impair the immune system. It delivers antibodies to help boost immunity and protect against infections. It offers a convenient, home-administered option for managing chronic immune deficiencies. The main indications of cutaquig are common variable immunodeficiency (CVID), x-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). Common Variable Immunodeficiency (CVID) is a primary immune disorder that results in low levels of antibodies, making individuals more vulnerable to infections. Symptoms include frequent bacterial infections, particularly in the respiratory and gastrointestinal systems. They are distributed through hospital pharmacies, specialty pharmacies, and home healthcare providers and are used in clinics, homecare, hospitals, and others.

What Is The Cutaquig Market Growth Forecast?

The growth in the forecast period can be attributed to growth of home infusion models, rising immune disorder prevalence, improved patient quality of life focus, expansion of specialty immunology clinics, advancements in plasma derived biologics. Major trends in the forecast period include rising adoption of subcutaneous immunoglobulin therapy, growing preference for home based immune treatments, expansion of primary immunodeficiency diagnosis, improved patient convenience through self administration, increasing demand for long term immune support.

Global Cutaquig Market Segmentation

1) By Indication: Common Variable Immunodeficiency (CVID), X-Linked Agammaglobulinemia, Severe Combined Immunodeficiency (SCID) 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Home Healthcare Providers 3) By End-Use: Clinics, Homecare, Hospitals, Other End-Uses

What Are The Drivers Of The Cutaquig Market?

The increase in prevalence of immunodeficiency diseases is expected to propel the growth of the cutaquig market. Immunodeficiency diseases are conditions where the immune system's ability to fight infections and diseases is compromised or entirely absent, due to genetic factors, underlying illnesses, or external influences such as medication or infection. Immunodeficiency diseases are rising due to genetic factors, aging populations, environmental pollution, unhealthy lifestyles, and increasing chronic illnesses, along with improved diagnostic capabilities, enhancing detection rates. Cutaquig, a subcutaneous immunoglobulin (SCIG), is used to treat primary immunodeficiency diseases by providing antibody replacement therapy to strengthen the immune system and reduce infections. For instance, in April 2025, according to the National Health Service, a UK-based government department, in the 2023–2024 period, more than 6,678 patients were recorded on immunoglobulin therapy for primary and secondary immunodeficiencies. Therefore, the increase in the prevalence of immunodeficiency diseases is driving growth in the cutaquig industry. The rise in the prevalence of infectious diseases is expected to propel the growth of the cutaquig market. Infectious diseases are disorders caused by microorganisms such as bacteria, viruses, fungi, or parasites. Infectious diseases are increasing because of global travel, urban growth, deforestation, climate shifts, drug resistance, and population surges. Cutaquig is used in infectious diseases to provide antibody support in patients with compromised immune systems, helping to reduce the frequency and severity of infections. For instance, in 2024, according to Health Equity Matters, an Australia-based nonprofit organization, the number of people estimated to be living with HIV increased by approximately 3.9% from 28,870 at the end of 2022 to 30,010 at the end of 2023. Therefore, the rise in the prevalence of infectious diseases is going to drive the growth of the cutaquig industry forward. The increase in the geriatric population is expected to boost the growth of the cutaquig market. The geriatric population refers to individuals aged 65 and older, who experience various age-related changes such as reduced skin elasticity, wrinkles, and fine lines. The increase in the geriatric population is due to factors such as improved healthcare, better living standards, and advances in medical treatments that have led to longer life expectancies. Cutaquig is used in the geriatric population to manage immunodeficiencies by enhancing immune function and reducing susceptibility to infections. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the increase in the geriatric population is propelling the growth of the cutaquig industry.

Key Players In The Global Cutaquig Market

Major companies operating in the cutaquig market are Octapharma AG

Regional Insights

North America was the largest region in the cutaquig market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cutaquig Market?

The cutaquig market consists of sales of infusion pumps, needle kits, syringes and connectors, and immunoglobulin (IgG) therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cutaquig Market Report 2026?

The cutaquig market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cutaquig industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.